{"nctId":"NCT02688556","briefTitle":"Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","startDateStruct":{"date":"2016-02","type":"ACTUAL"},"conditions":["Keratoconjunctivitis Sicca"],"count":745,"armGroups":[{"label":"OTX-101 0.09%","type":"EXPERIMENTAL","interventionNames":["Drug: cyclosporine"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: vehicle of OTX-101"]}],"interventions":[{"name":"cyclosporine","otherNames":["Seciera"]},{"name":"vehicle of OTX-101","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* History of dry eye syndrome (KCS) for a period of at least 6 months\n* Clinical diagnosis of bilateral KCS\n* Lissamine green conjunctival staining sum score of ≥ 3 to ≤ 9 out of a total possible score of 12 (scoring excludes superior zones 2 and 4) in the same eye at both the Screening and Baseline Visits.\n* Global symptom score (SANDE) ≥ 40 mm at both the Screening and Baseline Visits\n* Corrected Snellen visual acuity (VA) of better than 20/200 in each eye.\n\nExclusion Criteria:\n\n* Use of cyclosporine ophthalmic emulsion 0.05% (Restasis®) within 3 months prior to the Screening Visit.\n* Previous treatment failure (lack of efficacy) with cyclosporine ophthalmic emulsion 0.05% (Restasis).\n* Diagnosis of Sjögren's disease ˃ 5 years prior to the Screening Visit.\n* Clinical diagnosis or any history of seasonal and/or perennial allergic conjunctivitis.\n* Use of systemic or topical medications within 7 days prior to the Screening Visit or during the study period that are known to cause dry eye.\n* Use of any topical ophthalmic medications, prescription (including anti-glaucoma medications) or over the counter (including artificial tears), other than the assigned study medication during the study period.\n* Current active eye disease other than dry wyw syndrome (i.e., any disease for which topical or systemic ophthalmic medication is necessary).\n* History of herpes keratitis.\n* Corneal transplant\n* Corneal refractive surgery within 6 months prior to the Screening Visit or postoperative refractive surgery symptoms of dryness that have not resolved.\n* Cataract surgery within 3 months prior to the Screening Visit.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Tear Production","description":"Percentage of Eyes with Increase from Baseline of ≥ 10 mm in Schirmer's Test Score","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":null},{"groupId":"OG001","value":"9.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Conjunctival Staining","description":"change from baseline in total conjunctival staining score (lissamine green, modified National Eye Institute scale) at 12 weeks.\n\nConjunctival Lissamine Green Staining Grades ranged from 0 (No punctate stain in zone) to 3 (Densely concentrated micropunctate stain spots)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.53","spread":"1.927"},{"groupId":"OG001","value":"-1.16","spread":"2.2064"}]}]}]},{"type":"SECONDARY","title":"Central Corneal Staining","description":"change from baseline in central corneal staining score (fluorescein, modified NEI/FDA scale) at 12 weeks.\n\nThe Expanded National Eye Institute (NEI)/Industry Workshop Scale for Corneal Staining Score was used to grade each of the 5 areas of the cornea on a 0 (No punctate stain in area) to 4 (Severe diffuse (coalescent) macropunctate stain of the area) scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"0.533"},{"groupId":"OG001","value":"-0.26","spread":"0.588"}]}]}]},{"type":"SECONDARY","title":"Symptom Score","description":"change from baseline in modified Symptom Assessment in Dry Eye (SANDE) score at 12 weeks.\n\nA modified SANDE instrument was used to evaluate dry eye symptoms at each visit.\n\nSubjects were asked to indicate:\n\n1. frequency of dry and irritated eyes on a scale of 0 (rarely) to 100 (all the time); and\n2. severity of dry eyes on a scale of 0 (very mild) to 100 (severe) The global symptom score is the square root of the frequency score times the severity score and will be completed at each visit. (range 0 to 100)\n\nNegative change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.8","spread":"24.08"},{"groupId":"OG001","value":"-19.1","spread":"23.14"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":372},"commonTop":["Instillation site pain","Conjunctival hyperaemia","Sinusitis","Eye irritation","Headache"]}}}